Capital Group International Inc. CA Has $15.67 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Capital Group International Inc. CA reduced its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) by 44.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 60,056 shares of the pharmaceutical company’s stock after selling 47,117 shares during the period. Capital Group International Inc. CA’s holdings in Vertex Pharmaceuticals were worth $15,673,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Vertex Pharmaceuticals by 1.7% during the 4th quarter. BlackRock Inc. now owns 23,944,931 shares of the pharmaceutical company’s stock valued at $5,258,308,000 after acquiring an additional 397,036 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Vertex Pharmaceuticals by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 20,473,471 shares of the pharmaceutical company’s stock valued at $5,342,963,000 after acquiring an additional 317,629 shares in the last quarter. State Street Corp boosted its position in shares of Vertex Pharmaceuticals by 0.3% during the 4th quarter. State Street Corp now owns 12,356,915 shares of the pharmaceutical company’s stock valued at $2,713,579,000 after acquiring an additional 33,499 shares in the last quarter. Capital World Investors boosted its position in shares of Vertex Pharmaceuticals by 4.3% during the 4th quarter. Capital World Investors now owns 11,520,855 shares of the pharmaceutical company’s stock valued at $2,530,003,000 after acquiring an additional 478,553 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Vertex Pharmaceuticals by 15.2% during the 4th quarter. Alliancebernstein L.P. now owns 10,443,771 shares of the pharmaceutical company’s stock valued at $2,293,452,000 after acquiring an additional 1,374,923 shares in the last quarter. 91.33% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ VRTX opened at $284.86 on Thursday. The stock has a market cap of $73.05 billion, a P/E ratio of 23.03, a P/E/G ratio of 2.08 and a beta of 0.45. The firm has a 50 day moving average price of $287.96 and a 200 day moving average price of $271.43. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.36 and a current ratio of 4.50. Vertex Pharmaceuticals Incorporated has a 52-week low of $176.36 and a 52-week high of $305.95.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.12 by $0.48. The firm had revenue of $2.20 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 31.22%. The business’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.80 earnings per share. Analysts expect that Vertex Pharmaceuticals Incorporated will post 12.56 EPS for the current year.

Insider Activity

In other news, CEO Reshma Kewalramani sold 11,689 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $305.06, for a total value of $3,565,846.34. Following the completion of the transaction, the chief executive officer now owns 99,598 shares in the company, valued at $30,383,365.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Sangeeta N. Bhatia sold 621 shares of the business’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $278.77, for a total value of $173,116.17. Following the sale, the director now owns 5,282 shares of the company’s stock, valued at $1,472,463.14. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Reshma Kewalramani sold 11,689 shares of the business’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $305.06, for a total transaction of $3,565,846.34. Following the completion of the sale, the chief executive officer now directly owns 99,598 shares in the company, valued at approximately $30,383,365.88. The disclosure for this sale can be found here. Insiders sold 208,520 shares of company stock worth $59,937,985 over the last quarter. 0.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on VRTX shares. SVB Leerink initiated coverage on shares of Vertex Pharmaceuticals in a research report on Monday, May 23rd. They set a “market perform” rating and a $265.00 target price on the stock. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $291.00 to $307.00 and gave the company an “overweight” rating in a report on Friday, August 5th. HC Wainwright lifted their price target on shares of Vertex Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a report on Friday, August 5th. Maxim Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $325.00 price target for the company in a report on Wednesday, June 1st. Finally, Cowen lifted their price target on shares of Vertex Pharmaceuticals from $305.00 to $310.00 in a report on Monday, June 13th. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $291.65.

Vertex Pharmaceuticals Profile

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

See Also

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.